Table 1. Pharmacological parameters for canonical and noncanonical signaling by CXCR3.

Summary of the parameters obtained from fits of signaling assays (Figs. 1 and 2) from three to five independent experiments. EC₅₀ and E_max (expressed as a percentage of the CXCL11 signal) measurements for agonists were calculated from a three-parameter fit [y = Min + (Max − Min)/(1 + 10^LogEC50−X)]. For G_αi:β-arrestin complex formation, values were only calculated with CXCL11, VUF10661, and VUF11418, because the other agonists did not induce complex formation. If the three-parameter fit of ligand-receptor interaction produced a poor fit, then the data were omitted from the table. N/A, not applicable.

		Gαi:β-arrestin2	CXCR3:β-arrestin2	CXCR3:Gαi	cAMP inhibition
CXCL9	LogEC50	N/A	−7.7 ± 0.40	−7.6 ± 0.57	−7.9 ± 0.19
	E max	N/A	35 ± 9.0	79 ± 30	87 ± 10
CXCL10	LogEC50	N/A	−8.5 ± 0.17	−9.1 ± 0.55	−10 ± 0.15
	E max	N/A	76 ± 6.0	76 ± 19	110 ± 7.3
CXCL11	LogEC50	−7.6 ± 0.29	−8.2 ± 0.16	−8.8 ± 0.44	−9.6 ± 0.21
	E max	100 ± 20	100 ± 8.8	100 ± 21	100 ± 8.9
VUF10661	LogEC50	−6.0 ± 0.18	−6.4 ± 0.17	−6.3 ± 0.21	−7.2 ± 0.26
	E max	94 ± 10	92 ± 7.8	230 ± 25	160 ± 19
VUF11418	LogEC50	−5.9 ± 0.25	−6.7 ± 0.28	−5.7 ± 0.43	−6.6 ± 0.23
	E max	85 ± 13	52 ± 6.8	160 ± 43	160 ± 18